PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
The resinous sap (storax) has proven to be a strong antimicrobial agent, including activity against methicillin-resistant Staphylococcus aureus [PMID:26009686].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 37094052 (2006) — Chromosome-level genome assembly of American sweetgum (Liquidambar styraciflua, Altingiaceae). · Scientific data
- 2.PMID: 26009686 (2015) — Sweetgum: An ancient source of beneficial compounds with modern benefits. · Pharmacognosy reviews
- 3.PMID: 31220700 (2019) — Liquidambar styraciflua L.: A new potential source for therapeutic uses. · Journal of pharmaceutical and biomedical analysis
- 4.PMID: 33273244 (2020) — Contact Dermatitis From Gum Mastic (Pistacia lentiscus) and Gum Storax (Liquidambar styraciflua) in Mastisol-Allergic Patients. · Dermatitis : contact, atopic, occupational, drug
- 5.PMID: 36615553 (2023) — Chemical Evaluation of Liquidambar styraciflua L. Fruits Extracts and Their Potential as Anticancer Drugs.